Yang Yang, MD, PhD

Titles

Director, Hepatic Surgery Department
Vice Director, Organ Transplantation Center
Vice Chairman, Chinese Medical Association Organ Transplant Branch Youth Committee

Research Interests

Dr. Yang was an expert on liver surgery, performed more than 1000 liver transplantation and has accumulated a wealth of experience. He got a lot of grants from National Natural Science Foundation of China (NSFC) and Guangdong Province. His research group was mainly focused on finding new strategies for liver grafts protection, induction of immunological tolerance and he was devoted to clinical application of stem cell in liver transplantation.

Education and Experience

MD, Ph D, Sun Yat-sen University

Residency, First Affiliated Hospital of Sun Yat-sen University

Professor, Third Affiliated Hospital of Sun Yat-sen University

Honors and Awards

Second Prize of National Progress in Science and Technology, 2003

First Prize of Provincial Progress in Science and Technology, 2004, 2009, 2011

First Prize of Ministry of Education in Science and Technology, 2004, 2008

Publications

1.Guo Y, Wang J, Zhang L, Shen S, Guo R, Yang Y*, Chen W, Wang Y, Chen G, Shuai X. Theranostical Nanosystem-mediated Identification of an Oncogene and Highly Effective Therapy in Hepatocellular Carcinoma. Hepatology. 2015,63(4):1240-1255.

2.Ying-cai Zhang, En-ze Qu, Jie Ren, Qi Zhang, Rong-qin Zheng, YANG Yang*, and Gui-hua Chen. New Diagnosis and Therapy Model for Ischemic-Type Biliary Lesions Following Liver Transplantation-A Retrospective Cohort Study. PLoS One,2014, 9(9):e105795.

3.Deng Y, Yi S, Wang G, Cheng J, Zhang Y, Chen W, Tai Y, Chen S, Chen G, Liu W, Zhang Q, Yang Y*. Umbilical Cord-Derived Mesenchymal Stem Cells Instruct Dendritic Cells to Acquire Tolerogenic Phenotypes Through the IL-6-Mediated Upregulation of SOCS1. Stem Cells Dev. 2014, 23(17):2080-92.

4.Ye X, Guo Y, Zhang Q, Chen W, Hua X, Yang Yang*，CHEN Gui-hua.βKlotho Suppresses Tumor Growth in Hepatocellular Carcinoma by Regulating Akt/GSK-3β/Cyclin D1 Signaling Pathway PLoS ONE, 2013, 8(1): 55615-55622.

5.Tuanjie Li, Yang Yang(co-first author), Xuefeng Hua,et al. Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO. Cancer Letters 2012,318:154–161.

6.Guo-zheng Pan, Yang Yang(co-first author), Jian Zhang,et al. Bone marrow mesenchymal stem cells ameliorate hepaticischemia/reperfusion injuries via inactivation of the MEK/ERK signaling pathway in rats. Journal of Surgical Research. 2012; 1-14

7.ZHANG Ying-cai, ZHANG Qi, LI Hua, ZHANG Jian, WANG Gen-shu, XU Chi, YI Shu-hong, YI Hui-min, CAI Chang-jie, LU Min-qiang, YANG Yang*, CHEN Gui-hua. Prognostic factors for late mortality after liver transplantation for benign end-stage liver disease. Clin Med J. 2011;124(24) :4229-4235.

8.ZHANG Qi, YANG Yang(co-first author), ZHANG Jian, WANG Guo-ying, LIU Wei, QIU Dong-bo, HEI Zi-qing, YING Qi-long , CHEN Gui-hua. Efficient derivation of functional hepatocytes from mouse induced pluripotent stem cells by a combination of cytokines and sodium butyrate. Clin Med J, 2011; 124(22) : 3786-3793.

9.Gui-hua Chen, Yang Yang (co-first author), Min-qiang Lu, Chang-jie CAI, Qi ZHANG, Ying-cai ZHANG, Chi XU, Hua LI, Gen-shu WANG, Shu-hong YI, Jian ZHANG, Jun-feng ZHANG, Hui-min YI. Liver transplantation for end-stage alcoholic liver disease: A single-center experience from mainland China. Alcohol, 2010, 44:217-221.

10.YANG Yang, LI Hua, FU Bin-sheng, et al. Hepatic artery complications after orthotopic liver transplantation: interventional treatment or retansplantation? Clin Med J,2008,121(20):1997-2000.

11.YANG Yang, ZHANG Qi, CAI Chang-jie, et al. Prophylaxis of hepatitis B recurrence in post liver transplantation patients with lamivudine resistant YMDD mutation. Clin Med J, 2007,120(16):1400-1403.

Contact

Department of Liver Surgery and Liver Transplantation, Third Affiliated Hospital of Sun Yat-Sen University, Tianhe Road 600, Guangzhou 510630, China.

E-mail: yysysu@163.com

Phone: 86-20-85252191
Fax: 86-20-85252191